Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome – A single center retrospective analysis

• Published in: European journal of surgical oncology Vol. 49; no. 9; p. 106958
• Main Authors: Valstad, H., Eyjolfsdottir, B., Wang, Y., Kristensen, G.B., Skeie-Jensen, T., Lindemann, K.
• Format: Journal Article
• Language: English; Norwegian
• Published: England Elsevier Ltd 01.09.2023
• Subjects: Cancer-specific survival; Overall survival; Pelvic exenteration; Postoperative morbidity; Relapse-free survival; Vulvar cancer; Vulvar cancer; Pelvic exenteration; Cancer-specific survival; Postoperative morbidity; Overall survival; Relapse-free survival
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2023.06.010

Pelvic exenteration may be the only curative treatment for some patients with primary advanced or recurrent vulvar cancer but is associated with high morbidity. This study evaluated the clinical outcome of patients treated at a centralized service in Norway. This retrospective study included patients treated with pelvic exenteration for primary locally advanced or recurrent vulvar cancer between 1996 and 2019 at Oslo University Hospital, Norway. Complications were coded according to the contracted Accordion classification. Relapse free survival (RFS), cancer specific survival (CSS) and overall survival (OS) were estimated with the Kaplan Meier method. The 30 patients were followed for a median of 4.94 years (95%CI: 3.37-NR). Exenteration due to primary vulvar cancer was carried out in 16 (53%) patients, 14 (47%) had recurrent vulvar cancer. Free histopathological margins were achieved in 28 (93%) patients. The 90 days morbidity for grade 3 complications was 63%, predominantly wound/surgical flap infections, 7% had no complications. 90 days mortality was 3%. Five-year RFS was 26% (95% CI 8–48%), OS was 50% (95%CI: 29–69%) and CSS was 64% (95% CI 43–79%). There was no significant difference in survival between patients with primary vs recurrent disease. The 3-year CSS for patients with negative lymph nodes and positive lymph nodes was 70% (95% CI 47–84%) and 30% (95% CI 1–72%), respectively. Acceptable oncologic outcomes after pelvic exenteration for primary and recurrent vulvar cancer can be achieved if surgery is centralized. Careful patient selection is imperative due to significant postoperative morbidity and considerable risk of relapse.